{"filing":{"accession_number":"0001104659-26-102570","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-27","primary_document":"tm2624233d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926102570/tm2624233d1_8k.htm"},"events":[{"id":30147,"run_id":27629,"accession_number":"0001104659-26-102570","anchor_item_number":"1.03","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"BioXcel Therapeutics and its subsidiaries filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code on August 27, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The company will operate as debtors-in-possession and has filed for debtor-in-possession financing.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32665,"accession_number":"0001104659-26-102570","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 1.01 discloses entry into a material definitive agreement. The section explicitly states \"Entry into a Material Definitive Agreement\" and cross-references Item 1.03, which typically covers bankruptcy or receivership filings. The reference to Item 1.03 suggests this may involve a restructuring or significant transaction, though the exact nature is not detailed in the excerpt provided. Material definitive agreements under Item 1.01 typically relate to M\u0026A activity or significant business transactions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:09:46.759636+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32666,"accession_number":"0001104659-26-102570","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"BioXcel Therapeutics and its subsidiaries filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code on August 27, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The filing explicitly states the Debtors will operate as \"debtors-in-possession\" and have filed for debtor-in-possession financing. This is a terminal event materially threatening the registrant's continued existence as an independent operating company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:09:46.759636+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32665,"accession_number":"0001104659-26-102570","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 1.01 discloses entry into a material definitive agreement. The section explicitly states \"Entry into a Material Definitive Agreement\" and cross-references Item 1.03, which typically covers bankruptcy or receivership filings. The reference to Item 1.03 suggests this may involve a restructuring or significant transaction, though the exact nature is not detailed in the excerpt provided. Material definitive agreements under Item 1.01 typically relate to M\u0026A activity or significant business transactions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:09:46.759636+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-28"},{"id":32666,"accession_number":"0001104659-26-102570","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"BioXcel Therapeutics and its subsidiaries filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code on August 27, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The filing explicitly states the Debtors will operate as \"debtors-in-possession\" and have filed for debtor-in-possession financing. This is a terminal event materially threatening the registrant's continued existence as an independent operating company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:09:46.759636+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-28"}]}